The DoHAICs Study Expansion Phase
ConditionHCC - Hepatocellular Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTianjin Medical University Cancer Institute and Hospital
About this trial
We explored the efficacy and safety of the first-line treatment of unresectable hepatocellular carcinoma with donafenib combined with hepatic artery infusion chemotherapy (HAIC) and sintilimab .
Eligibility criteria
Qualifiers
Voluntarily participate in the trial and provide written informed consent.
Age between 18 and 80 years (inclusive), regardless of gender.
Patients with hepatocellular carcinoma (HCC) clinically diagnosed per the "Standard for Diagnosis and Treatment of Primary Liver Cancer (2024 Edition)" or confirmed by histology/cytology.
Patients with inoperable or metastatic hepatocellular carcinoma.
Disqualifiers
Histologically/cytologically confirmed components such as fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, or cholangiocarcinoma.
The patient has undergone potentially curative treatment with no evidence of that disease for 5 years.
Successfully resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other carcinoma in situ.
Diffuse tumor lesions.
Trial design
Treatments tested in this trial
- Donafenib
- sintilimab
- HAIC
Treatment groups
90 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov